Why we built Chassiscell
Founded in 2025 at Boston's Albany Street research corridor, Chassiscell was built around a specific observation: synthetic biology programs at pharma and biotech keep redoing the same cell chassis groundwork — and each time, they absorb the full cost in time and personnel before reaching the biology they actually came to do.
The same problem, repeated
Rebecca, Marcus, and Sofia worked in adjacent spaces along Boston's Albany Street research corridor — different programs, overlapping problems. Over several years, they watched a pattern repeat: a biosynthesis or cell engineering program would arrive at chassis debugging six months in, having initially assumed the host organism was a solved question. The strain had come from a plate inventory. It competed with the new pathway for malonyl-CoA or IPP. The native regulatory circuits attenuated expression under production conditions. Plasmid burden climbed with each additional part, and growth slowed in ways that took weeks to attribute.
The chassis was never the science the program was trying to do. It was the substrate the science required. But it was being treated as an afterthought — purchased from ATCC or pulled from a legacy stock, with the expectation that its behavior under novel conditions would be predictable. It rarely was.
In late 2025, the three of them decided the pattern was worth addressing as a dedicated discipline. They founded Chassiscell with a focused premise: apply the Design-Build-Characterize rigor of a serious engineering program to the chassis selection and modification problem — and deliver that work to R&D programs through a structured collaboration model, rather than expecting every team to reinvent the methodology independently.
Chassiscell is not trying to be a full-service CRO or a strain catalog. We build a focused set of characterized chassis backgrounds in the organisms that matter for biosynthesis and cell engineering programs — and we collaborate closely enough with each partner to understand what "characterized" needs to mean for their specific program.
Boston's medical innovation corridor
- Address
- 650 Albany Street, Innovation Lab 4
- City, State
- Boston, MA 02118
- Phone
- +1 (617) 226-0589
- [email protected]
Why Boston?
650 Albany Street sits within the BU Medical Campus life science node — a concentrated cluster of research, clinical, and early-stage biotech activity that is genuinely difficult to replicate elsewhere. BU Medical is across the street. The Longwood Medical and Academic Area — Harvard Medical School, DFCI, Brigham and Women's, and a dense surrounding layer of biotech companies — is a short drive. Kendall Square in Cambridge is fifteen minutes across the river.
For a company whose work depends on tight technical collaboration with pharma and biotech R&D programs, that proximity matters practically. It means we can be in a partner's lab for a technical discussion without a flight. It means our scientific advisor network overlaps naturally with the academic institutions our partners draw on. It means the regulatory, legal, and commercialization infrastructure that early-stage biotech collaborations require is close enough to use.
Founded
Chassiscell established in Boston by Rebecca Hartmann, Marcus Tran, and Sofia Bellini at 650 Albany Street
Lab Operational
First chassis construction work begins at Innovation Lab 4, 650 Albany Street
Angel Funding
Angel-backed to expand chassis development capacity, instrument the characterization pipeline, and build the first partner cohort
Building something that requires a chassis?
We're speaking with a small number of potential partners for our first cohort. If your program requires a cell chassis built specifically for your compound class and operating conditions, we'd like to hear about it.
Talk to Our Team